Seattle Genetics, Inc.

Seagen Inc.

Zymogenetics, Inc.

Ares Trading S.a.

Mayo Foundation for Medical Education and Research

Eric Sievers

Dana Kennedy

Michael Sun

Nathan Ihle

Herve Broly

Arnaud Ythier

Hans-Peter Gerber

Ezogelin Oflazoglu

Alan F Wahl

Sharon J Busby

May Kung Sutherland

Stephen M Ansell

Jonathan G Drachman

Grant Risdon

Jan Öhrström

Ivan Nestorov

Tim Lewis

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5. 

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.

Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A&#x2212; is a Stretcher unit, and p is from about 3 to about 5. 

Weekly dosing regimens for anti-CD30 VC-PAB-MMAE antibody drug-conjugates

The present invention provides methods and compositions for treatment of hyperproliferative disorders and cancers, including multiple myeloma and Waldenstr&#xf6;m's macroglobulinemia, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules

Methods for the retreatment of CD30-expressing lymphomas with an anti-CD30 vc-PAB-MMAE antibody-drug conjugate are provided.

Post-relapse treatment of CD30 expressing lymphomas

Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided.

Combination therapy with antibody-drug conjugates

The present invention provides methods and compositions for treatment of B-cell malignancies, including non-Hodgkin's lymphoma, comprising administering to a patient in need of the treatment a TACI-Ig fusion molecule in amount sufficient to suppress proliferation-inducing functions of BlyS and APRIL.

Methods for treating B-cell malignancies using a TACI-Ig fusion molecule

Growing community of inventors

Bothell, WA, United States of America

Eric Sievers